Search clinical trials for: MK-1454

Total 1967 results

Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

Respiratory Syncytial Virus | Respiratory Tract Infection

United States, Chile, Colombia, Korea, Republic of, South Africa, Spain
Merck Sharp & Dohme LLC

Completed

Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005)

Respiratory Syncytial Viruses

United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

Respiratory Syncytial Virus Infection

United States, Argentina, Belgium, Canada, Chile, China, Colombia, Denmark, Finland, France, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Peru, Philippines, Poland, Romania, South Africa, Thailand, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Completed

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States, Australia, Austria, Brazil, France, Israel, Korea, Republic of, Norway, Spain, United Kingdom
University of Southern California
National Institute on Aging (NIA); Northern California Institute of Research... and other collaborators

Recruiting

Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4)

Dementia | Alzheimer Disease | Mild Cognitive Impairment

United States, Canada
Merck Sharp & Dohme LLC

Completed

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Lymphoma | Solid Tumors

United States, Korea, Republic of, France, Israel, United Kingdom
Sumitomo Pharma America, Inc.

Recruiting

Phase 1 Study of Oral TP-1454

Advanced Solid Tumor | Anal Cancer

United States
Merck Sharp & Dohme LLC

Recruiting

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

RSV Infection

United States, Australia, Canada, Chile, Colombia, Czechia, Germany, Greece, Malaysia, Mexico, New Zealand, Puerto Rico, Singapore, South Africa, Spain, Taiwan, Turkey, United Kingdom, Japan, Peru, Hong Kong, France, Thailand, Finland, ... and more
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

Advanced or Metastatic Solid Tumors

United States, Canada, Israel, Netherlands
Northwestern University
National Institute on Aging (NIA)

Recruiting

Tau PET Imaging in Atypical Dementias

Primary Progressive Aphasia With Suspected Alzheimer's Disease

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

Prostate Cancer

United States, Belgium, Italy, Czech Republic, Hungary, Netherlands, Poland, Russian Federation
Columbia University
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations

Tauopathies | Frontotemporal Dementia (FTD) | Frontotemporal Lobar Degeneration (FTLD)

United States
Memory Pharmaceuticals
Hoffmann-La Roche

Unknown

A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients (P50)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Terminated

A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)

Osteosarcoma | Sarcoma, Ewing's | Peripheral Neuroectodermal Tumor
Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Mayo Clinic
National Institute on Deafness and Other Communication Disorders (NIDCD)

Recruiting

Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech

Primary Progressive Aphasia | Apraxia of Speech | PPA | Non-fluent Aphasia | Primary Progressive Non-fluent Aphasia

United States
Renovis

Unknown

Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia

Neuralgia | Peripheral Nervous System Disease | Shingles

United States
Memory Pharmaceuticals

Completed

Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Renovis

Unknown

Study of REN-1654 in Patients With Sciatica Pain

Sciatica | Radiculopathy | Herniated Disc

United States
Boehringer Ingelheim

Completed

Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of BIBB 1464 MS in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food

Healthy
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)

Polysomnography
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of MK-8266 (MK-8266-001)

Hypertension
University of Southern California
Avid Radiopharmaceuticals; Alzheimer's Therapeutic Research Institute; Alzheimer...

Completed

18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study (LEARN-Tau)

Cognition Disorders

United States
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Bioavailability of [14C]-SK-1404 ADME & IV Microtracer Study

Nocturia

United Kingdom
Molecular Insight Pharmaceuticals, Inc.

Completed

Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection

Prostate Cancer

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404

Prostate Cancer

United States
Invicro

Completed

Assessment of the Biodistribution and Safety of [18F]MNI-1054

Healthy Volunteers

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer

Prostate Cancer

United States
Merck Sharp & Dohme LLC

Completed

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Solid Tumors

United States, Canada, Switzerland
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Advanced Cancer
Merck Sharp & Dohme LLC

Recruiting

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

HIV | HIV Pre-exposure Prophylaxis

United States, South Africa, Israel
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study of MK-3614 (MK-3614-002)

Hypertension
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)

Type 2 Diabetes
Molecular Insight Pharmaceuticals, Inc.

Completed

Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer (proSPECT-AS)

Prostate Cancer

United States, Canada
Merck Sharp & Dohme LLC

Withdrawn

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

Asthma
Merck Sharp & Dohme LLC

Completed

A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)

Asthma
SecuraBio

Completed

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145

Healthy

United States
Merck Sharp & Dohme LLC

Completed

A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

Hepatitis C Virus Infection
Merck Sharp & Dohme LLC

Completed

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)

Hypertension

United States
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

Asthma

United States, Australia, New Zealand, South Africa
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

Hepatitis C
Merck Sharp & Dohme LLC

Recruiting

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Israel, Italy, Mexico, New Zealand, Poland, Sweden, Turkey, United Kingdom, Greece, Russian Federation
Merck Sharp & Dohme LLC

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)

Hypertension | Isolated Systolic Hypertension
Arcutis Biotherapeutics, Inc.

Completed

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) (ARRECTOR)

Scalp Psoriasis

United States, Canada

Search clinical trials for: MK-1454

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations